Abstract
Magneto- and Electroencephalography (MEG/EEG) are important techniques for the diagnosis and pre-surgical evaluation of epilepsy. Yet, in current cryogen-based MEG systems the sensors are offset from the scalp, which limits the signal-to-noise ratio (SNR) and thereby the sensitivity to activity from deep structures such as the hippocampus. This effect is amplified in children, for whom adult-sized fixed-helmet systems are typically too big. Moreover, ictal recordings with fixed-helmet systems are problematic because of limited movement tolerance. Optically Pumped Magnetometers (OPMs) can be placed directly on the scalp, thereby improving SNR and consequently the sensitivity to, and localisation accuracy of, epileptiform activity. In addition, recording during seizures becomes feasible with these wearable sensors.
We aimed to demonstrate these advantages of OPMs in a clinical population. Three adults with known weak sources of interictal epileptiform discharges (IEDs), along with three children with focal epilepsy and one adult with frequent seizures underwent MEG recordings using a 12-channel OPM-system and a 306-channel cryogen-based whole-head system. Performance of the two systems was compared in terms of IED-rate and SNR.
In one patient the OPMs detected IEDs that were not found with the SQUID-system. In one patient the spike yield was higher for the OPM data (9.00 versus 6.76), with negligible difference in SNR compared to the SQUID data (3.85 versus 3.93; U = -2.86, d = -0.14). This was also the case for a patient with a spike yield that was comparable to that for the SQUID data (after accounting for unilateral coverage with the OPMs; SNR 4.47 versus 4.57; U = -3.81, d = -0.14). For one patient the spike yield (11.03 versus 24.50) and SNR (4.39 versus 4.05; U = 9.53, d = -0.36) were both lower for the OPMs. In two patients no IEDs were found with either system. Importantly, the wearability of OPMs enabled the recording of seizure activity in a patient with hyperkinetic movements during the seizure. The observed ictal onset and semiology were in agreement with previous video- and stereo-EEG recordings.
Overall, OPM data were very much comparable to those obtained with a cryogenic system: OPMs outperformed SQUIDs for two of the four patients with IEDs, with either a higher spike yield, or an ability to detect IEDs that were not observable in the SQUID data. For three patients the SNRs of IEDs were (slightly) lower in the OPM data than in the SQUID data, but with negligible effect sizes for two of these patients. The relatively cheap technology, in combination with reduced running and maintenance costs, means that OPM-based MEG could be used more widely than current MEG systems, and may become an affordable alternative to scalp EEG, with the potential benefits of increased spatial accuracy, reduced sensitivity to volume conduction/field spread, and increased sensitivity to deep sources. Wearable MEG thus provides an unprecedented opportunity for epilepsy, and given its patient-friendliness, we envisage that it will not only be used for presurgical evaluation of epilepsy patients, but also for diagnosis after a first seizure.
Competing Interest Statement
M.J.B. is a director of Cerca Magnetics Limited, a spin-out company whose aim is to commercialise aspects of OPM-MEG technology. Cerca products include bi-planar coils such as those used in this work. N.H., M.J.B. and R.B. hold founding equity in Cerca Magnetics Limited, and N.H. and R.B. sit on the scientific advisory board.
Clinical Trial
NL8920
Funding Statement
This work was supported by the Dutch Epilepsy Foundation, project number EC19-05
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical Ethics Committee of the Vrije Universiteit Medical Centre gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and user-developed codes are available upon reasonable request to the corresponding author under the condition of an existing collaboration agreement.
